Ketamine Therapy Use Rises Among U.S. Veterans: Policy and Research Gaps

Veterans Increasingly Turn to Ketamine Therapy for Depression

Growing numbers of U.S. military veterans are seeking ketamine therapy for relief from depression, reflecting both unmet mental health needs and the expanding use of off-label psychedelic treatments. This trend, reported in November 2026, highlights a shift toward alternative interventions as traditional options often fall short, especially for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) prevalent in veteran populations.

Ketamine, originally approved by the U.S. Food and Drug Administration (FDA) as an anesthetic, is not formally indicated for depression except in the form of esketamine (Spravato), a nasal spray approved in 2019 for TRD. However, intravenous and intramuscular ketamine are widely used off-label in clinics across the United States, including in settings that cater specifically to veterans.

Mechanism, Access, and Clinical Context

Ketamine acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, modulating glutamate signaling in the brain and producing rapid, though often transient, antidepressant effects. Unlike selective serotonin reuptake inhibitors (SSRIs), ketamine can relieve symptoms within hours, a critical feature for those with acute suicidality or severe depression.

Despite its promise, access to ketamine therapy remains uneven. The U.S. Department of Veterans Affairs (VA) has implemented limited ketamine and esketamine programs at select medical centers, but most veterans receive treatment in private clinics, often paying out-of-pocket. Insurance coverage is inconsistent, and there is no standardized protocol for dosing, monitoring, or integration with other therapies. This patchwork approach can leave vulnerable patients exposed to variable quality and oversight.

Policy, Regulatory, and Research Implications

The growing off-label use of ketamine among veterans exposes regulatory ambiguities and underscores the need for more robust clinical evidence. The FDA has not approved racemic ketamine for depression, and the agency has issued public advisories warning about unregulated use and potential risks. Meanwhile, the VA's own guidance limits ketamine therapy to carefully selected cases and mandates close monitoring.

Clinical trials of ketamine for depression, including several registered on ClinicalTrials.gov, have demonstrated short-term efficacy but leave questions about long-term safety, optimal dosing, and comparative effectiveness. Notably, few large-scale, randomized controlled trials (RCTs) have been conducted specifically in veteran or PTSD populations. This evidence gap complicates policy decisions and insurance reimbursement, and may inadvertently drive veterans toward less regulated providers.

One under-discussed challenge is the potential for divergent standards of care between VA and private clinics, leading to confusion among patients and providers about what constitutes evidence-based treatment. This fragmentation may also hinder data collection and the development of best practices.

Risks, Unknowns, and Clinical Caveats

Ketamine therapy carries significant risks, including dissociation, blood pressure spikes, potential for misuse, and unknown long-term effects with repeated dosing. The lack of standardized protocols and variable provider training further complicate risk management. While some veterans report dramatic improvements, others experience only transient relief or adverse effects.

There is also concern about the emergence of "ketamine clinics" with limited psychiatric oversight, raising ethical and safety questions. The absence of clear regulatory frameworks means that quality assurance, informed consent, and integration with ongoing mental health care can vary widely. For veterans with complex trauma histories, these gaps may increase the risk of poor outcomes or disengagement from care.

Outlook: Toward Evidence-Based, Equitable Access

The rising use of ketamine therapy among veterans signals both the limitations of current mental health systems and the urgent need for innovation. Policymakers, regulators, and researchers face a dual challenge: expanding access to potentially life-saving treatments while ensuring safety, efficacy, and equity.

Future directions include large-scale, veteran-focused RCTs, clearer insurance and VA coverage policies, and standardized clinical guidelines. Importantly, any expansion of ketamine therapy should be accompanied by robust data collection and integration with comprehensive mental health services. As the field evolves, the experience of veterans may serve as a bellwether for broader psychedelic policy and practice in the United States.

By Dr. Alex Monroe, PhD, Science & Policy Editor. How we research: This article was reviewed by Dr. Alex Monroe on 2026-11-13. Primary sources include FDA advisories, VA clinical guidance, and ClinicalTrials.gov trial registries.